Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2014 1
2018 1
2021 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Low dose naltrexone for induction of remission in Crohn's disease.
Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N. Parker CE, et al. Cochrane Database Syst Rev. 2018 Apr 1;4(4):CD010410. doi: 10.1002/14651858.CD010410.pub3. Cochrane Database Syst Rev. 2018. PMID: 29607497 Free PMC article.
Low dose naltrexone, an opioid antagonist, has garnered interest as a potential therapy. ...SELECTION CRITERIA: Randomized controlled trials of low dose naltrexone (LDN) for treatment of active Crohn's disease were included. DATA COLLECTI …
Low dose naltrexone, an opioid antagonist, has garnered interest as a potential therapy. ...SELECTION CRITERIA: Randomi …
Low dose naltrexone for induction of remission in Crohn's disease.
Segal D, Macdonald JK, Chande N. Segal D, et al. Cochrane Database Syst Rev. 2014 Feb 21;(2):CD010410. doi: 10.1002/14651858.CD010410.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2018 Apr 01;4:CD010410. doi: 10.1002/14651858.CD010410.pub3. PMID: 24558033 Updated.
Low dose naltrexone, an opioid antagonist, has garnered interest as a potential therapy. ...SELECTION CRITERIA: Randomized controlled trials of low dose naltrexone (LDN) for treatment of active Crohn's disease were included. DATA COLLECTI …
Low dose naltrexone, an opioid antagonist, has garnered interest as a potential therapy. ...SELECTION CRITERIA: Randomi …
A review of the potential role of methylnaltrexone in opioid bowel dysfunction.
Foss JF. Foss JF. Am J Surg. 2001 Nov;182(5A Suppl):19S-26S. doi: 10.1016/s0002-9610(01)00783-8. Am J Surg. 2001. PMID: 11755893 Review.
Methylnaltrexone (MNTX) is a novel quaternary derivative of naltrexone that does not cross the blood-brain barrier and acts as a selective peripheral opioid receptor antagonist. In normal volunteers, intravenous or oral MNTX reverses opioid-induced reduction in bowel mo …
Methylnaltrexone (MNTX) is a novel quaternary derivative of naltrexone that does not cross the blood-brain barrier and acts as a sele …
Psychopharmacologic Therapies for Irritable Bowel Syndrome.
Törnblom H, Drossman DA. Törnblom H, et al. Gastroenterol Clin North Am. 2021 Sep;50(3):655-669. doi: 10.1016/j.gtc.2021.04.005. Epub 2021 Jul 1. Gastroenterol Clin North Am. 2021. PMID: 34304793 Review.
Psychopharmacologic therapies are beneficial in reducing symptoms when treating irritable bowel syndrome (IBS) and other disorders of gut-brain interaction (DGBI). Noradrenaline, serotonin, and dopamine are neurotransmitters of key importance in psychopharmacology and pain …
Psychopharmacologic therapies are beneficial in reducing symptoms when treating irritable bowel syndrome (IBS) and other disorders of gut …
Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study.
Yuan SC, Foss FJ, O'Connor M, Osinski J, Roizen FM, Moss J. Yuan SC, et al. Pain. 1999 Dec;83(3):631-635. doi: 10.1016/S0304-3959(99)00162-1. Pain. 1999. PMID: 10568873
In this preliminary study, we evaluated the effects of methylnaltrexone, a peripheral opioid-receptor antagonist, on chronic opioid-induced gut motility and transit changes in four subjects with chronic methadone-induced constipation. ...Our preliminary results demo …
In this preliminary study, we evaluated the effects of methylnaltrexone, a peripheral opioid-receptor antagonist, on chronic opioid-induced …